A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

被引：12
|
作者：
Facon, Thierry [1 ]
Hulin, Cyrille [2 ]
Dimopoulos, Meletios A. [3 ]
Belch, Andrew [4 ]
Meuleman, Nathalie [5 ]
Mohty, Mohamad [6 ]
Chen, Wen-Ming [7 ]
Kim, Kihyun [8 ]
Zamagni, Elena [9 ]
Rodriguez-Otero, Paula [10 ]
Renwick, William [11 ]
Rose, Christian [12 ]
Tempescul, Adrian [13 ]
Palumbo, Antonio [14 ]
Guo, Shien [15 ]
Sturniolo, Michael [16 ]
Ervin-Haynes, Annette [16 ]
Fermand, Jean-Paul [17 ]
机构：
[1] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France
[2] CHU BORDEAUX, Bordeaux, France
[3] Univ Athens, Sch Med, Athens 11528, Greece
[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[5] Univ Libre Bruxelles, Jules Bordet Insitute, Dept Hematol, Brussels, Belgium
[6] St Antoine Hosp, Dept Haematol, Paris, France
[7] Beijing Chaoyang Hosp, Beijing, Peoples R China
[8] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[9] Azienda Osped Univ, Bologna, Italy
[10] Univ Navarra Clin, Pamplona, Spain
[11] Western Hlth, St Albans, Australia
[12] Hop St Vincent, Dept Hematol, Lille, France
[13] CHU Brest, Dept Hematol, F-29285 Brest, France
[14] Univ Turin, Turin, Italy
[15] Evidera, Boston, MA USA
[16] Celgene Corp, Summit, NJ USA
[17] Hop St Louis, AP HP, Serv Immunohematol, Paris, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.4239.4239
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in BelaRd trial
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vassiliki
    Syrigou, Rodanthi
    Eleutherakis-Papaiakovou, Evangelos
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Kastritis, Efstathios
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S102 - S103
  • [32] Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Kanellias, Nikolaos
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Papaiakovou, Evangelos Eleutherakis
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BLOOD, 2022, 140 : 7267 - 7268
  • [33] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [34] Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma
    Sharpley, Faye A.
    Djebbari, Faouzi
    Fourali, Samih
    Kothari, Jaimal
    Lynes, John A.
    McLain-Smith, Susan
    Ramasamy, Karthik
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 732 - 736
  • [35] Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
    Delforge, Michel
    Minuk, Leonard
    Eisenmann, Jean-Claude
    Arnulf, Bertrand
    Canepa, Letizia
    Fragasso, Alberto
    Leyvraz, Serge
    Langer, Christian
    Ezaydi, Yousef
    Vogl, Dan T.
    Giraldo-Castellano, Pilar
    Yoon, Sung-Soo
    Zarnitsky, Charles
    Escoffre-Barbe, Martine
    Lemieux, Bernard
    Song, Kevin
    Bahlis, Nizar Jacques
    Guo, Shien
    Monzini, Mara Silva
    Ervin-Haynes, Annette
    Houck, Vanessa
    Facon, Thierry
    HAEMATOLOGICA, 2015, 100 (06) : 826 - 833
  • [36] LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL
    Facon, T.
    Dimopoulos, M. A.
    Dispenzieri, A.
    Catalano, J. V.
    Belch, A.
    Hulin, C.
    Cavo, M.
    Pinto, A.
    Weisel, K. C.
    Ludwig, H.
    Bahlis, N.
    Banos, A.
    Tiab, M.
    Delforge, M.
    Cavenagh, J.
    Geraldes, C.
    Lee, J. J.
    Chen, C.
    Oriol, A.
    De La Rubia, J.
    Qiu, L.
    White, D.
    Binder, D.
    Anderson, K. C.
    Moreau, P.
    Attal, M.
    Knight, R.
    Chen, G.
    Van Oostendorp, J.
    Jacques, C. J.
    Ervin-Haynes, A.
    Benboubker, L.
    HAEMATOLOGICA, 2014, 99 : 220 - 221
  • [37] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
    Bahlis, Nizar
    Facon, Thierry
    Usmani, Saad Z.
    Kumar, Shaji K.
    Plesner, Torben
    Orlowski, Robert Z.
    Touzeau, Cyrille
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael E.
    Venner, Christopher P.
    Weisel, Katja C.
    Krevvata, Maria
    Pei, Huiling
    Wang, Jianping
    Van Rampelbergh, Rian
    Ukropec, Jon
    Uhlar, Clarissa M.
    Kobos, Rachel
    Perrot, Aurore
    BLOOD, 2019, 134
  • [38] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [39] Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
    Baz, Rachid C.
    Shain, Kenneth H.
    Hussein, Mohamad A.
    Lee, Ji-Hyun
    Sullivan, Daniel M.
    Oliver, Elizabeth Finley
    Nardelli, Lisa A.
    Nodzon, Lisa A.
    Zhao, Xiuhua
    Ochoa-Bayona, Jose Leonel
    Nishihori, Taiga
    Dalton, William S.
    Alsina, Melissa
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) : 62 - 67
  • [40] Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group
    Rajkumar, S. V.
    Jacobus, S.
    Callander, N.
    Fonseca, R.
    Vesole, D.
    Williams, M.
    Abonour, R.
    Siegel, D.
    Greipp, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345